2005
DOI: 10.1016/j.vaccine.2004.11.044
|View full text |Cite
|
Sign up to set email alerts
|

Policymakers’ views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
65
0
2

Year Published

2007
2007
2018
2018

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 100 publications
(69 citation statements)
references
References 15 publications
2
65
0
2
Order By: Relevance
“…However, these policy makers repeated the need for regional incidence data to determine where limited resources can have the greatest impact. 27 In our qualitative interviews with policy makers and health administrators in Zanzibar, they indicated that current Health Management Information System (HMIS) surveillance data on typhoid fever was insufficient to make decisions about intervention efforts. Some policy makers and administrators also perceived the "problem" of typhoid fever as primarily restricted to mainland Tanzania.…”
Section: Discussionmentioning
confidence: 99%
“…However, these policy makers repeated the need for regional incidence data to determine where limited resources can have the greatest impact. 27 In our qualitative interviews with policy makers and health administrators in Zanzibar, they indicated that current Health Management Information System (HMIS) surveillance data on typhoid fever was insufficient to make decisions about intervention efforts. Some policy makers and administrators also perceived the "problem" of typhoid fever as primarily restricted to mainland Tanzania.…”
Section: Discussionmentioning
confidence: 99%
“…Many vaccines using Salmonella mutants have failed due to either over-or underattenuation of the vaccine strain (29,58). Sadly, when strains that confer protection against typhoid were developed, economic pressures prevented the implementation of a vaccine program (6). Currently, translating the successes of clinical trials performed on the ⌬aroC/⌬ssaV mutant in healthy Western subjects to individuals in developing countries is a significant challenge (52).…”
Section: Vaccine Developmentmentioning
confidence: 99%
“…For instance, in the case of Shigella and oral cholera vaccines in Asia, uncertainty about the disease burden and high prices of the current vaccines and their moderate protection levels have inhibited their adoption. 92 Moreover, the cost of vaccine delivery in middle and low income countries should not be overlooked, as large new vaccines such as rotavirus can lead to bottlenecks that inhibit the delivery of other vaccines. [93][94][95] Evaluating the economics of vaccines for nearly all types of diarrheal diseases bring particular common challenges.…”
Section: Discussionmentioning
confidence: 99%